METHOD OF PROVIDING READILY AVAILABLE CELLULAR MATERIAL DERIVED FROM PERIPHERAL BLOOD

• US 20070087324A1
• Filed: 11/30/2006
• Published: 04/19/2007
• Est. Priority Date: 02/28/2005
• Status: Abandoned Application

• Current Assignee: Donnie Rudd
• Original Assignee: Donnie Rudd
• Inventors: RUDD, Donnie
• Application Number:
  US11/565,021
• Publication Number:
  US 20070087324A1
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 33/34 Copper; Compounds thereof
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/125 : Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/22 : Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 5/0647 : Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Process for preparing a peripheral blood cell composition in a TVEMF-bioreactor.

Claims

1. A process for preparing a peripheral blood stem cell composition comprising the steps of:

a. placing a peripheral blood mixture in a culture chamber of a TVEMF-bioreactor; and

b. subjecting the peripheral blood mixture to a TVEMF and TVEMF-expanding the peripheral blood stem cells in the TVEMF-bioreactor to prepare the peripheral blood stem cell composition.

2. The process according to claim 1, wherein said TVEMF is about 0.05 to about 6.0 gauss.

3. The process according to claim 1, wherein said TVEMF-expanding continues until the number per volume of TVEMF-expanded peripheral blood stem cells is more than 7 times the number per volume of peripheral blood stem cells placed in the TVEMF-bioreactor.

4. The process according to claim 1, further comprising collecting peripheral blood prior to placing the peripheral blood mixture in a TVEMF-bioreactor.

5. The process of claim 4, wherein said peripheral blood is human peripheral blood.

6. The process according to claim 1, further comprising collecting thawed cryopreserved peripheral blood from a peripheral blood storage facility prior to adding the peripheral blood to the peripheral blood mixture.

7. The process of claim 1, further comprising a step of removing toxic material from the peripheral blood mixture prior to TVEMF-expansion.

8. The process of claim 1, wherein the TVEMF-bioreactor has an integral TVEMF source.

9. The process of claim 1, wherein the TVEMF-bioreactor has an adjacent TVEMF source.

10. The process of claim 1, wherein the peripheral blood mixture comprises CD34+/CD38−

peripheral blood stem cells separated from other peripheral blood components.

11. The process of claim 1, wherein the peripheral blood mixture comprises a buffy coat separated from other peripheral blood components.

12. The process of claim 1, wherein the peripheral blood mixture comprises peripheral blood free of red blood cells.

13. The process of claim 1, further comprising the steps of transferring the TVEMF-expanding cells of the pheripheral blood stem cell composition into a cryogenic container having a temperature, and lowering the temperature of the cryogenic container to a temperature of from −

120°

C. to−

196°

C. at a controlled rate.

14. The process of claim 13, further comprising a step of removing toxic material from the peripheral blood stem cell composition prior to lowering the temperature to a temperature of from −

120°

C. to −

196°

C. at a controlled rate.

15. The process of claim 13, further comprising, after the step of lowering the temperature, a step of maintaining the temperature of the cryogenic container to a temperature of from −

120°

C. to −

196°

C., for a period of time.

16. The process of claim 15, wherein said period of time is at least 1 year.

17. The process of claim 15, further comprising, after said lowering and maintaining of temperature, a step of increasing the temperature of the cryogenic container at a controlled rate to a temperature suitable for introducing the peripheral blood stem cell composition to a mammal.

18. The process of claim 17, wherein toxic material has been removed from said increased temperature peripheral blood stem cell composition.

19. The process of claim 13, further comprising the step of adding a cryopreservative to the TVEMF-expanded cells of the peripheral blood stem cell composition before the step of lowering the temperature.